These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 26996183)

  • 1. [Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Patients with Decompensated Cirrhosis].
    Gwak GY
    Korean J Gastroenterol; 2016 Mar; 67(3):137-41. PubMed ID: 26996183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Indications for Treatment].
    Kim KA
    Korean J Gastroenterol; 2016 Mar; 67(3):123-6. PubMed ID: 26996180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of the treatment of chronic hepatitis C virus infection in cirrhosis.
    Vezali E; Aghemo A; Colombo M
    Clin Ther; 2010 Dec; 32(13):2117-38. PubMed ID: 21316532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Chronic Hepatitis C Genotype 2 and 3].
    Jung YK
    Korean J Gastroenterol; 2016 Mar; 67(3):132-6. PubMed ID: 26996182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in the treatment of hepatitis C.
    Lawrence SP
    Adv Intern Med; 2000; 45():65-105. PubMed ID: 10635046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Chronic Hepatitis C Genotype 1].
    Park SH
    Korean J Gastroenterol; 2016 Mar; 67(3):127-31. PubMed ID: 26996181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consensus guidelines for the management of hepatitis C infection.
    Consensus Guidelines Committee for the Management of Hepatitis C Infection
    Saudi Med J; 2003 Jul; 24 Suppl 2():S99-118. PubMed ID: 25121186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation.
    Crippin JS; McCashland T; Terrault N; Sheiner P; Charlton MR
    Liver Transpl; 2002 Apr; 8(4):350-5. PubMed ID: 11965579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy of hepatitis C: patients with cirrhosis.
    Schalm SW; Fattovich G; Brouwer JT
    Hepatology; 1997 Sep; 26(3 Suppl 1):128S-132S. PubMed ID: 9305677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C Virus Therapy for Decompensated and Posttransplant Patients.
    Dailey F; Ayoub WS
    J Clin Gastroenterol; 2017 Mar; 51(3):215-222. PubMed ID: 28178089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens.
    Younossi ZM; Stepanova M; Nader F; Jacobson IM; Gane E; Nelson D; Lawitz E; Hunt SL
    Hepatology; 2014 Jun; 59(6):2161-9. PubMed ID: 24710669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cirrhosis in hepatitis C virus-infected patients: a review for practitioners new to hepatitis C care.
    Muir AJ
    Top Antivir Med; 2014; 22(4):685-9. PubMed ID: 25398070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical efficacy and safety of the combination therapy of peginterferon alpha and ribavirin in cirrhotic patients with HCV infection].
    Cheong HR; Woo HY; Heo J; Yoon KT; Kim DU; Kim GH; Kang DH; Song GA; Cho M
    Korean J Hepatol; 2010 Mar; 16(1):38-48. PubMed ID: 20375641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status of hepatitis C virus infection in Korea.
    Suh DJ; Jeong SH
    Intervirology; 2006; 49(1-2):70-5. PubMed ID: 16166792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis.
    Hung CH; Lee CM; Lu SN; Wang JH; Hu TH; Tung HD; Chen CH; Chen WJ; Changchien CS
    J Viral Hepat; 2006 Jun; 13(6):409-14. PubMed ID: 16842444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Application of direct antiviral drugs in special patients with HCV infection].
    Jiang C; Liu CY; Shao S; Gao YH
    Zhonghua Gan Zang Bing Za Zhi; 2018 Apr; 26(4):316-320. PubMed ID: 29996347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.
    Saab S; Hunt DR; Stone MA; McClune A; Tong MJ
    Liver Transpl; 2010 Jun; 16(6):748-59. PubMed ID: 20517909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, tolerability, and efficacy of pegylated-interferon alfa-2a plus ribavirin in HCV-related decompensated cirrhotics.
    Tekin F; Gunsar F; Karasu Z; Akarca U; Ersoz G
    Aliment Pharmacol Ther; 2008 Jun; 27(11):1081-5. PubMed ID: 18346186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of patients with hepatitis C and cirrhosis.
    Wright TL
    Hepatology; 2002 Nov; 36(5 Suppl 1):S185-94. PubMed ID: 12407593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. News and challenges in the treatment of hepatitis C in liver transplantation.
    Coilly A; Roche B; Duclos-Vallée JC; Samuel D
    Liver Int; 2016 Jan; 36 Suppl 1():34-42. PubMed ID: 26725895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.